Resources
49 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 9/8/2023 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) has updated the 2018 document which outlines best practices for implementing and operating recovery housing. Assisting individuals with recovery housing is critical in the journey of recovery and can lead to the improvement of health, reduce overdose risks, and sustain recovery.
Posted 7/26/2023 (updated 3/28/2024)
During this session, attendees had the opportunity to have topic-focused discussions among their peers in smaller, facilitated breakout groups. The groups all convened in the ballroom, and attendees had the opportunity for sharing best practices and obstacles, asking questions, and participating in other forms of discussion throughout the session.
Posted 2/7/2023 (updated 3/27/2024)
The Centers for Disease Control and Prevention (CDC) funded an evaluation study of post-overdose outreach programs in Massachusetts known as the PRONTO Study. This study group assessed the evidence on post-overdose outreach.
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).
Posted 6/6/2022 (updated 3/27/2024)
This session highlighted over a decade of Community Apgar research and its implementation supporting community development for physician recruitment and retention in rural FQHCs and CAHs. This presentation also included ongoing implementation of the program through collaboration with 3RNet and the use of a “Factors Book” which can highlight community assets and focus recruitment efforts to better meet community needs.
Posted 2/11/2022 (updated 4/11/2024)
This packet presents Implementation III grantees with tools and strategies to support implementation activities that expand the options for SUD/OUD services across the care spectrum, thereby helping rural residents in your community to prevent SUD/OUD, access treatment, and move toward recovery.
Posted 12/22/2021 (updated 3/26/2024)
This guide provides rural health care leaders and teams with foundational knowledge, strategies, and resources to understand the impact of social determinants of health (SDOH) on patients and communities. It organizes key information and resources to help the busy manager support and lead education and discussion with front-line staff. This guide focuses on (1) understanding the need and opportunity around addressing SDOH, (2) using local data to support decision making, and (3) involving team members to plan and implement action steps.
Posted 10/26/2021 (updated 4/3/2024)
Posted 8/25/2021 (updated 4/2/2024)
HRSA’s Health Centers Program published new research briefs exploring health center capacity in maternity care deserts, differences in clinical quality measures among Appalachian and non-Appalachian health centers, and the role of health centers in providing medication-assisted treatment. The briefs were developed through the UDS Mapper—a tool that helps evaluate the geographic reach, penetration, and growth of the Health Center Program and its relationship to other federally-linked health resources.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.